The global pharmaceutical landscape is undergoing its most significant transformation in decades. For procurement teams and supply chain managers, the ground rules of sourcing active pharmaceutical ingredients (APIs) and intermediates have fundamentally changed. Understanding these shifts isn't just about staying informed-it's about making decisions that protect your supply continuity.
The Numbers Behind the Growth
The global pharmaceutical intermediates market is on a steady growth trajectory, valued at approximately USD 39 billion in 2024 and projected to reach USD 68 billion by 2033, growing at a CAGR of 6.37%. The broader API market reflects even larger scale-global API market size reached USD 245.26 billion in 2025 and is expected to grow to USD 457.75 billion by 2034 at a CAGR of 7.26%. Behind these numbers lie real drivers: an aging global population, rising prevalence of chronic diseases, and the continued expansion of personalized medicine.
But growth is only half the story. The real question for procurement teams is: How stable is the supply chain behind this growth?
The China-India Dynamic: Concentration and Dependency
Today, approximately 68% of active pharmaceutical ingredients in the European market come from Asia, with China supplying 24% and India 37%. In antibiotics, the concentration is even more striking: 47% of global production is based in China, 27% in India, and only 23% in Europe.
Perhaps most revealing is the relationship between the two Asian manufacturing giants. India-the world's largest generic medicine manufacturer-relies on China for an estimated 70-80% of its active pharmaceutical ingredients. This means that Indian pharmaceutical exports, which supply markets globally, depend heavily on Chinese raw material inputs.
Recent analysis shows that among the key starting materials (KSMs) required for API production, 58% depend on single-country supply, concentrated in China (41%) and India (16%). For 679 APIs-representing 37% of those analyzed-at least one KSM depends exclusively on Chinese supply.
The Policy Shock: US Tariffs on Pharmaceutical Imports
The most significant policy development in recent months came in April 2026, when the United States formally invoked Section 232 of the Trade Expansion Act of 1962 to impose tariffs of up to 100% on imported patented drugs and corresponding pharmaceutical ingredients, citing national security concerns.
According to FDA data cited in the policy announcement, 53% of patented drugs in the US are manufactured overseas, with domestic production of patented APIs at just 15%. The policy framework establishes a tiered approach: companies that sign Most-Favored-Nation pricing agreements and commit to onshoring production can access 0% tariffs; those committing only to onshoring face 20% initial tariffs, rising to 100% within four years; those with no commitments face the full 100% tariff.
Generic drugs and biosimilars are currently exempt, but the administration has indicated it will reassess this position within one year, retaining the option to extend tariffs to generic products in the future.
Quality Compliance Under Increased Scrutiny
While policy and trade dynamics reshape the market, regulatory scrutiny on quality has intensified. In 2025 and early 2026, the FDA issued a series of Warning Letters to India-based API manufacturers, citing significant deviations from Current Good Manufacturing Practice (CGMP) regulations.
One notable case involved an Indian manufacturer where inspectors found that the quality unit failed to document the review and release of multiple API batches, did not prepare and maintain batch records, and exhibited multiple data integrity violations. Another inspection uncovered failures in facility design to prevent contamination, inadequate process validation, and missing stability testing programs. These cases illustrate a broader trend: regulatory agencies worldwide are applying higher standards and more frequent inspections, with less tolerance for compliance gaps.
Redefining Supply Chain Resilience
What does this mean for procurement strategy in 2026 and beyond? Industry experts note that the CDMO and fine chemicals sector is now being shaped by three critical forces: geopolitical regionalization and the increasing requirement for domestic US manufacturing capacity; the competition against clients' internal build strategies; and structural market bipolarity as consolidation accelerates.
The old playbook-built on predictable trade flows, concentrated manufacturing hubs, and long-term vendor relationships optimized for cost-is breaking. As one industry analysis puts it: "What's breaking in 2026 is not just the supply chain, but the underlying operating model that effectively governed the sector for the last 30 years." The metric that matters most is no longer necessarily "cheapest," but "guaranteed."
What This Means for Your Sourcing Strategy
Based on the current landscape, here are three practical considerations for procurement teams evaluating API and intermediate suppliers:
1. Demand visibility beyond Tier 1. Understand not just who your immediate supplier is, but where their KSMs originate. Single-country concentration in the upstream chain can create hidden vulnerabilities.
2. Prioritize documented compliance. Regulatory pressure is not easing. Suppliers should be able to demonstrate a track record of successful inspections, robust quality systems, and verifiable data integrity practices.
3. Value stability alongside price. In an environment where tariffs, geopolitical shifts, and supply disruptions are increasingly common, a supplier's ability to maintain consistent delivery and transparent communication may outweigh marginal cost differences.
The pharmaceutical supply chain in 2026 demands a new approach: one that balances cost efficiency with genuine resilience, and transactional relationships with strategic partnership.
